Saturday 17 October 2026
Export TNDM’s income statement to Excel — free account
Tandem Diabetes Care, Inc.
TNDM Healthcare Medical Devices
Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024. In the quarter to June 2026, revenue grew 5.77%, EPS grew 60.3%, free cash flow fell 146.3% and total debt rose 94.9%, each against the same quarter a year earlier.
16.17
0.35
−2.12%
Follow TNDM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.82 | 1.46 | 1.28 | 1.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
99.38 | 151.08 | 118.62 | (30.07) | |
P/B ratio |
6.18 | 9.53 | 9.90 | 7.99 | |
Price to Tangible BV |
6.22 | 9.59 | 9.97 | 8.04 | |
EV/Sales |
0.81 | 1.47 | 1.31 | 1.14 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(92.32) | (153.92) | 68.47 | (215.09) | |
EV/FCF |
(8.61) | (15.13) | (18.43) | (12.40) | |
Quick Ratio |
1.76 | 1.89 | 2.87 | 2.44 | |
Current Ratio |
2.44 | 2.55 | 3.58 | 3.18 | |
Net Debt/EBITDA |
0.52 | 1.51 | (2.41) | (15.29) | |
Debt/Assets |
35.40% | 35.19% | 52.17% | 52.21% | |
Debt/Equity |
2.33 | 2.00 | 4.55 | 4.62 | |
Asset Turnover |
1.10 | 1.10 | 0.99 | 1.03 | |
Operating CF/Net income |
(0.39) | (16.62) | (0.54) | 1.64 | |
Capex/Depreciation |
(0.88) | (2.09) | (1.45) | (0.96) | |
Interest Coverage |
(11.07) | 4.00 | (7.91) | (5.63) | |
Research and Development Expense of Revenue |
19.54% | 15.86% | 18.62% | 18.44% | |
Selling, General and Administrative Expense of Revenue |
43.51% | 38.95% | 43.76% | 43.86% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.48% | 6.93% | 6.33% | 6.18% | |
Graham Net Nets |
(0.15) | (0.07) | (0.10) | (0.21) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(25.12%) | (13.97%) | (7.30%) | (6.16%) | |
Free Cash Flow Yield |
(11.49%) | (6.69%) | (5.56%) | (9.20%) | |
Revenue per Share |
3.68 | 4.32 | 3.61 | 3.69 | |
Operating CF per Share |
0.12 | 0.15 | 0.16 | (0.50) | |
Capex per Share |
(0.06) | (0.10) | (0.09) | (0.06) | |
Free Cash Flow per Share |
0.06 | 0.05 | 0.07 | (0.56) | |
Cash per Share |
4.72 | 4.35 | 8.34 | 6.61 | |
Shareholders Equity per Share |
1.97 | 2.31 | 1.94 | 1.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.97 | 2.31 | 1.94 | 1.89 | |
Free Cash Flow |
4.17 | 3.10 | 4.79 | (38.68) | |
Working Capital |
364.40 | 375.42 | 639.14 | 551.63 | |
Capital Expenditures |
(4.09) | (6.68) | (6.27) | (4.05) | |
Net Current Asset Value |
(124.74) | (107.80) | (133.89) | (219.17) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
116.56 | 140.04 | 133.62 | 145.25 | |
Average Payables |
48.12 | 45.90 | 59.83 | 59.98 | |
Average Inventory |
144.86 | 139.19 | 133.78 | 138.84 | |
Average Assets |
916.19 | 924.39 | 1,037.77 | 1,014.97 | |
Average Common Equity |
185.34 | 209.13 | 143.85 | 131.84 |
Columns are period end dates